
Opinion|Videos|April 28, 2025
Clinical Manifestation of ATTR-CM and Red Flag Symptoms
Panelists discuss how recognizing key clinical manifestations and red flag symptoms, such as bilateral carpal tunnel syndrome, spinal stenosis, and trigger fingers, is critical for early diagnosis and intervention in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), particularly in those with unexplained heart failure or arrhythmias.
Advertisement
Episodes in this series

Summary for Physicians: Clinical Manifestations and Red Flag Symptoms of ATTR-CM
Clinical Manifestations of ATTR-CM:
- Cardiac symptoms:
- Heart failure (HF), often with restrictive cardiomyopathy
- Atrial arrhythmias that are resistant to ablation procedures
- Bradyarrhythmias and tachyarrhythmias
- Pacemaker dependence in advanced cases
- Extracardiac symptoms:
- Bilateral carpal tunnel syndrome (CTS): Often a key early sign of the disease
- Spinal stenosis: May cause discomfort or neurological deficits
- Trigger fingers: Common in patients with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM)
- Pulmonary embolism: Can occur in advanced stages
- Electrocardiogram findings:
- May show signs of low-voltage QRS complexes, heart block, or other arrhythmias typical of restrictive cardiomyopathy
- Imaging:
- Echocardiography and cardiac MRI often show characteristic features of restrictive cardiomyopathy or amyloid deposits.
- Chest x-ray may show evidence of HF.
- Laboratory findings:
- Elevated biomarkers such as NT-proBNP and troponins can be seen in cardiac involvement.
- Genetic testing can confirm the diagnosis of hATTR-CM.
Red Flag Symptoms for hATTR-CM:
- Persistent bilateral CTS, spinal stenosis, and trigger fingers should raise suspicion of hATTR-CM, especially in patients with unexplained HF or arrhythmias.
- A history of family members with similar symptoms or genetic mutations associated with ATTR-CM further supports the diagnosis.
Early recognition of these symptoms is essential for timely diagnosis and intervention in patients with ATTR-CM.
Advertisement
Related to this article

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.
Advertisement
Advertisement
Trending on HCPLive
1
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
2
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
3
What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers
4
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
5

